01—Abstract
Summary
Summary of the 8-K filed January 7, 2026. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has filed a Form 8-K disclosing preliminary financial information and guidance updates for the fourth quarter and full year 2025.
The company expects to report significant acquired In-Process Research & Development (IPR&D) and milestones expenses totaling $1.3 billiona pre-tax for the fourth quarter of 2025. This expense is anticipated to have an unfavorable impact of $0.71 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. This disclosure impacts AbbVie's previously issued guidance.
The full-year 2025 adjusted diluted earnings per share guidance has been revised to a range of $9.90 to $9.94b, incorporating this expense. Similarly, the fourth-quarter 2025 adjusted diluted earnings per share guidance is now projected to be between $2.61 and $2.65.
Investors should note that these figures are preliminary and subject to change as financial closing procedures are completed. The company also reiterates its cautionary note regarding forward-looking statements and the inherent risks and uncertainties in its business operations.
02—Key points
Key Highlights
- AbbVie expects $1.3 billion in acquired IPR&D and milestones expense for Q4 2025 (pre-tax).
- This expense negatively impacts Q4 2025 GAAP and adjusted non-GAAP diluted EPS by an estimated $0.71 per share.
- Full-year 2025 adjusted diluted EPS guidance is updated to a range of $9.90 - $9.94.
- Q4 2025 adjusted diluted EPS guidance is revised to a range of $2.61 - $2.65.
- The company emphasizes that these results are preliminary estimates and subject to financial statement closing procedures.
- Acquired IPR&D and milestones expenses are inherently unpredictable and not typically forecasted by AbbVie.
03—Questions
Frequently Asked Questions
What is the primary reason for the revised earnings guidance?
The primary reason for the revised earnings guidance is a significant pre-tax expense of $1.3 billion related to acquired In-Process Research & Development (IPR&D) and milestones, which AbbVie expects to incur in the fourth quarter of 2025.
How will this IPR&D and milestone expense affect AbbVie's earnings per share?
The estimated $1.3 billion expense is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share by approximately $0.71 for the fourth quarter of 2025.
Are the reported figures final?
No, the figures disclosed in this report are preliminary estimates. AbbVie states that the results for the quarter ended December 31, 2025, have not been finalized and are subject to financial statement closing procedures. There is no assurance that the final results will not differ from these estimates.
Why does AbbVie not forecast acquired IPR&D and milestones expenses?
AbbVie does not typically forecast acquired IPR&D and milestones expenses because the occurrence and timing of these transactions are uncertain and depend on future events such as collaborations, licensing agreements, and asset acquisitions.
04—Continue